Pet Cancer Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Therapy (Surgery, Radiotherapy, Chemotherapy, Immunotherapy, Others), By Animal Type (Canine, Feline, Others), By Cancer Type (Lymphoma, Mast Cell Cancer, Mammary & Squamous Cell Cancer, Others), By Company, and By Region
The global pet cancer therapeutics market is anticipated to observe an impressive growth during the forecast period, 2023-2027. The major factors include growing consciousness of pet’s health and increasing incidences of cancer among animals. Cancer in pets is one of the primary reasons for death, globally. Nowadays, pets have better chances to get diagnosed with cancer due which early adoption of treatment plans are required, which bolster the growth of the market. The other factors supporting the market's growth are rise in pet ownership or animal adoption, advancement in diagnostic techniques and rise in R&D initiatives. Additionally, heavy investments in research and development activities coupled with oncology treatment and management in pets offers lucrative opportunities to the market players in upcoming years.
Increasing Awareness regarding Pet Healthcare and Treatments
The increasing domestication of animals and growing concerns regarding pet health among the people are supporting the market growth. In 2021, number of pet dogs owned worldwide was 471 million. People are becoming more thoughtful about their pet’s health and are expending generously on the best available animal therapeutics. Average American yearly spending on pet dogs is estimated to be USD 1201. In addition, growing pet’s health awareness programs is augmenting the growth of the market. For instance, the Blue Buffalo Foundation and the Pet Cancer Awareness Program (PCA) are some initiatives which raise awareness and provide information to the pet parents.
Increasing Prevalence of Cancer
The growing prevalence of cancer among pet animals, is a contributing factor for the growth of the market. Cancer is one of the key causes of death in pets, mostly in dogs that are older than 10 years. According to the Veterinary Cancer Society, in 2017, cancer was the foremost cause of death in 47% of dogs, especially those that are over the age of 10, and 32% of cats. Leukemia and lymphoma are very common cancer in cats and certain breeds of elderly dogs. In 2017, Animal Cancer Foundation published a study, which revealed approximately around 25% of all dogs will develop a tumor at some point in their life.
Technological Advancements
Various technological advancements, such as the development of highly targeted and specific cures for animal cancer treatment with minimal side effects, are also supporting the market growth. Increasing R&D initiatives for cancer management is propelling the market growth, as various anti-cancer therapies are launching for veterinary cancer treatment. For instance, in 2017, Jackson Laboratory launched Tallwood Canine Cancer Research Initiative (TCCRI), to generate a biobank of dog tumors for giving insights on cancer cure through research. Also, organizations such as Animal Cancer Foundation, Veterinary Cancer Society, Petco Foundation and PetCure Oncology are doing oncology research such as canine cancer genome project to gain the knowledge related to the genetic makeup of cancer tumors in animals. The foremost focus is on the development of anticancer drugs and improvising their effectiveness and reducing their toxic effects on the pet’s body.
Market Segmentation
The global pet cancer therapeutics market is segmented into therapy, animal type, cancer type, and company. Based on therapy, the market is divided into surgery, radiotherapy, chemotherapy, immunotherapy, and others. Based on animal type, the market is divided into canine, feline, and others. Based on cancer type, the market is segmented into lymphoma, mast cell cancer, mammary & squamous cell cancer, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to rising domestication and rise in the occurrence of pet cancers in the country.
Market Players
C.H. Boehringer Sohn Ko. KG, ELIAS Animal Health, LLC, Zoetis Inc., AB Science S.A., Karyopharm Therapeutics, Inc., Vivesto AB, Merial Inc., Elanco Animal Health, Inc., Dechra Pharmaceuticals PLC (Anivive Lifesciences), and Torigen Pharmaceuticals Inc. are some of the leading companies operating in the market.
Report Scope:
In this report, global pet cancer therapeutics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in Pet Cancer Therapeutics Market
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
Increasing Awareness regarding Pet Healthcare and Treatments
The increasing domestication of animals and growing concerns regarding pet health among the people are supporting the market growth. In 2021, number of pet dogs owned worldwide was 471 million. People are becoming more thoughtful about their pet’s health and are expending generously on the best available animal therapeutics. Average American yearly spending on pet dogs is estimated to be USD 1201. In addition, growing pet’s health awareness programs is augmenting the growth of the market. For instance, the Blue Buffalo Foundation and the Pet Cancer Awareness Program (PCA) are some initiatives which raise awareness and provide information to the pet parents.
Increasing Prevalence of Cancer
The growing prevalence of cancer among pet animals, is a contributing factor for the growth of the market. Cancer is one of the key causes of death in pets, mostly in dogs that are older than 10 years. According to the Veterinary Cancer Society, in 2017, cancer was the foremost cause of death in 47% of dogs, especially those that are over the age of 10, and 32% of cats. Leukemia and lymphoma are very common cancer in cats and certain breeds of elderly dogs. In 2017, Animal Cancer Foundation published a study, which revealed approximately around 25% of all dogs will develop a tumor at some point in their life.
Technological Advancements
Various technological advancements, such as the development of highly targeted and specific cures for animal cancer treatment with minimal side effects, are also supporting the market growth. Increasing R&D initiatives for cancer management is propelling the market growth, as various anti-cancer therapies are launching for veterinary cancer treatment. For instance, in 2017, Jackson Laboratory launched Tallwood Canine Cancer Research Initiative (TCCRI), to generate a biobank of dog tumors for giving insights on cancer cure through research. Also, organizations such as Animal Cancer Foundation, Veterinary Cancer Society, Petco Foundation and PetCure Oncology are doing oncology research such as canine cancer genome project to gain the knowledge related to the genetic makeup of cancer tumors in animals. The foremost focus is on the development of anticancer drugs and improvising their effectiveness and reducing their toxic effects on the pet’s body.
Market Segmentation
The global pet cancer therapeutics market is segmented into therapy, animal type, cancer type, and company. Based on therapy, the market is divided into surgery, radiotherapy, chemotherapy, immunotherapy, and others. Based on animal type, the market is divided into canine, feline, and others. Based on cancer type, the market is segmented into lymphoma, mast cell cancer, mammary & squamous cell cancer, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to rising domestication and rise in the occurrence of pet cancers in the country.
Market Players
C.H. Boehringer Sohn Ko. KG, ELIAS Animal Health, LLC, Zoetis Inc., AB Science S.A., Karyopharm Therapeutics, Inc., Vivesto AB, Merial Inc., Elanco Animal Health, Inc., Dechra Pharmaceuticals PLC (Anivive Lifesciences), and Torigen Pharmaceuticals Inc. are some of the leading companies operating in the market.
Report Scope:
In this report, global pet cancer therapeutics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
- Pet Cancer Therapeutics Market, By Therapy:
- Surgery
- Radiotherapy
- Chemotherapy
- Immunotherapy
- Others
- Pet Cancer Therapeutics Market, By Animal Type:
- Canine
- Feline
- Others
- Pet Cancer Therapeutics Market, By Cancer Type:
- Lymphoma
- Mast Cell Cancer
- Mammary & Squamous Cell Cancer
- Others
- Pet Cancer Therapeutics Market, By Region:
- North America
- United States
- Canada
- Mexico
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- Europe & CIS
- Germany
- France
- United Kingdom
- Spain
- Italy
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Company Profiles: Detailed analysis of the major companies present in Pet Cancer Therapeutics Market
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. IMPACT OF COVID-19 ON GLOBAL PET CANCER THERAPEUTICS MARKET
5. VOICE OF CUSTOMER
6. GLOBAL PET CANCER THERAPEUTICS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Therapy (Surgery, Radiotherapy, Chemotherapy, Immunotherapy, Others)
6.2.2. By Animal Type (Canine, Feline, Others)
6.2.3. By Cancer Type (Lymphoma, Mast Cell Cancer, Mammary & Squamous Cell Cancer, Others)
6.2.4. By Company (2021)
6.2.5. By Region
6.3. Market Map
7. NORTH AMERICA PET CANCER THERAPEUTICS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Therapy
7.2.2. By Animal Type
7.2.3. By Cancer Type
7.2.4. By Country
7.3. North America: Country Analysis
7.3.1. United States Pet Cancer Therapeutics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Therapy
7.3.1.2.2. By Animal Type
7.3.1.2.3. By Cancer Type
7.3.2. Mexico Pet Cancer Therapeutics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Therapy
7.3.2.2.2. By Animal Type
7.3.2.2.3. By Cancer Type
7.3.3. Canada Pet Cancer Therapeutics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Therapy
7.3.3.2.2. By Animal Type
7.3.3.2.3. By Cancer Type
8. EUROPE PET CANCER THERAPEUTICS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Therapy
8.2.2. By Animal Type
8.2.3. By Cancer Type
8.2.4. By Country
8.3. Europe: Country Analysis
8.3.1. France Pet Cancer Therapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Therapy
8.3.1.2.2. By Animal Type
8.3.1.2.3. By Cancer Type
8.3.2. Germany Pet Cancer Therapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Therapy
8.3.2.2.2. By Animal Type
8.3.2.2.3. By Cancer Type
8.3.3. United Kingdom Pet Cancer Therapeutics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Therapy
8.3.3.2.2. By Animal Type
8.3.3.2.3. By Cancer Type
8.3.4. Italy Pet Cancer Therapeutics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Therapy
8.3.4.2.2. By Animal Type
8.3.4.2.3. By Cancer Type
8.3.5. Spain Pet Cancer Therapeutics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Therapy
8.3.5.2.2. By Animal Type
8.3.5.2.3. By Cancer Type
9. ASIA-PACIFIC PET CANCER THERAPEUTICS MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Therapy
9.2.2. By Animal Type
9.2.3. By Cancer Type
9.2.4. By Country
9.3. Asia-Pacific: Country Analysis
9.3.1. China Pet Cancer Therapeutics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Therapy
9.3.1.2.2. By Animal Type
9.3.1.2.3. By Cancer Type
9.3.2. India Pet Cancer Therapeutics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Therapy
9.3.2.2.2. By Animal Type
9.3.2.2.3. By Cancer Type
9.3.3. Japan Pet Cancer Therapeutics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Therapy
9.3.3.2.2. By Animal Type
9.3.3.2.3. By Cancer Type
9.3.4. South Korea Pet Cancer Therapeutics Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Therapy
9.3.4.2.2. By Animal Type
9.3.4.2.3. By Cancer Type
9.3.5. Australia Pet Cancer Therapeutics Market Outlook
9.3.5.1. Market Size & Forecast
9.3.5.1.1. By Value
9.3.5.2. Market Share & Forecast
9.3.5.2.1. By Therapy
9.3.5.2.2. By Animal Type
9.3.5.2.3. By Cancer Type
10. SOUTH AMERICA PET CANCER THERAPEUTICS MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Therapy
10.2.2. By Animal Type
10.2.3. By Cancer Type
10.2.4. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Pet Cancer Therapeutics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Therapy
10.3.1.2.2. By Animal Type
10.3.1.2.3. By Cancer Type
10.3.2. Argentina Pet Cancer Therapeutics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Therapy
10.3.2.2.2. By Animal Type
10.3.2.2.3. By Cancer Type
10.3.3. Colombia Pet Cancer Therapeutics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Therapy
10.3.3.2.2. By Animal Type
10.3.3.2.3. By Cancer Type
11. MIDDLE EAST AND AFRICA PET CANCER THERAPEUTICS MARKET OUTLOOK
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Therapy
11.2.2. By Animal Type
11.2.3. By Cancer Type
11.2.4. By Country
11.3. MEA: Country Analysis
11.3.1. South Africa Pet Cancer Therapeutics Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Therapy
11.3.1.2.2. By Animal Type
11.3.1.2.3. By Cancer Type
11.3.2. Saudi Arabia Pet Cancer Therapeutics Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Therapy
11.3.2.2.2. By Animal Type
11.3.2.2.3. By Cancer Type
11.3.3. UAE Pet Cancer Therapeutics Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Therapy
11.3.3.2.2. By Animal Type
11.3.3.2.3. By Cancer Type
11.3.4. Egypt Pet Cancer Therapeutics Market Outlook
11.3.4.1. Market Size & Forecast
11.3.4.1.1. By Value
11.3.4.2. Market Share & Forecast
11.3.4.2.1. By Therapy
11.3.4.2.2. By Animal Type
11.3.4.2.3. By Cancer Type
11.3.5. Turkey Pet Cancer Therapeutics Market Outlook
11.3.5.1. Market Size & Forecast
11.3.5.1.1. By Value
11.3.5.2. Market Share & Forecast
11.3.5.2.1. By Therapy
11.3.5.2.2. By Animal Type
11.3.5.2.3. By Cancer Type
12. MARKET DYNAMICS
12.1. Drivers
12.2. Challenges
13. MARKET TRENDS & DEVELOPMENTS
14. COMPETITIVE LANDSCAPE
14.1. C.H. Boehringer Sohn Ko. KG
14.2. ELIAS Animal Health, LLC
14.3. Zoetis Inc.
14.4. AB Science S.A.
14.5. Karyopharm Therapeutics, Inc.
14.6. Vivesto AB
14.7. Merial Inc.
14.8. Elanco Animal Health, Inc.
14.9. Dechra Pharmaceuticals PLC (Anivive Lifesciences)
14.10. Torigen Pharmaceuticals Inc.
15. STRATEGIC RECOMMENDATIONS
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. IMPACT OF COVID-19 ON GLOBAL PET CANCER THERAPEUTICS MARKET
5. VOICE OF CUSTOMER
6. GLOBAL PET CANCER THERAPEUTICS MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Therapy (Surgery, Radiotherapy, Chemotherapy, Immunotherapy, Others)
6.2.2. By Animal Type (Canine, Feline, Others)
6.2.3. By Cancer Type (Lymphoma, Mast Cell Cancer, Mammary & Squamous Cell Cancer, Others)
6.2.4. By Company (2021)
6.2.5. By Region
6.3. Market Map
7. NORTH AMERICA PET CANCER THERAPEUTICS MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Therapy
7.2.2. By Animal Type
7.2.3. By Cancer Type
7.2.4. By Country
7.3. North America: Country Analysis
7.3.1. United States Pet Cancer Therapeutics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Therapy
7.3.1.2.2. By Animal Type
7.3.1.2.3. By Cancer Type
7.3.2. Mexico Pet Cancer Therapeutics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Therapy
7.3.2.2.2. By Animal Type
7.3.2.2.3. By Cancer Type
7.3.3. Canada Pet Cancer Therapeutics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Therapy
7.3.3.2.2. By Animal Type
7.3.3.2.3. By Cancer Type
8. EUROPE PET CANCER THERAPEUTICS MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Therapy
8.2.2. By Animal Type
8.2.3. By Cancer Type
8.2.4. By Country
8.3. Europe: Country Analysis
8.3.1. France Pet Cancer Therapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Therapy
8.3.1.2.2. By Animal Type
8.3.1.2.3. By Cancer Type
8.3.2. Germany Pet Cancer Therapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Therapy
8.3.2.2.2. By Animal Type
8.3.2.2.3. By Cancer Type
8.3.3. United Kingdom Pet Cancer Therapeutics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Therapy
8.3.3.2.2. By Animal Type
8.3.3.2.3. By Cancer Type
8.3.4. Italy Pet Cancer Therapeutics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Therapy
8.3.4.2.2. By Animal Type
8.3.4.2.3. By Cancer Type
8.3.5. Spain Pet Cancer Therapeutics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Therapy
8.3.5.2.2. By Animal Type
8.3.5.2.3. By Cancer Type
9. ASIA-PACIFIC PET CANCER THERAPEUTICS MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Therapy
9.2.2. By Animal Type
9.2.3. By Cancer Type
9.2.4. By Country
9.3. Asia-Pacific: Country Analysis
9.3.1. China Pet Cancer Therapeutics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Therapy
9.3.1.2.2. By Animal Type
9.3.1.2.3. By Cancer Type
9.3.2. India Pet Cancer Therapeutics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Therapy
9.3.2.2.2. By Animal Type
9.3.2.2.3. By Cancer Type
9.3.3. Japan Pet Cancer Therapeutics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Therapy
9.3.3.2.2. By Animal Type
9.3.3.2.3. By Cancer Type
9.3.4. South Korea Pet Cancer Therapeutics Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Therapy
9.3.4.2.2. By Animal Type
9.3.4.2.3. By Cancer Type
9.3.5. Australia Pet Cancer Therapeutics Market Outlook
9.3.5.1. Market Size & Forecast
9.3.5.1.1. By Value
9.3.5.2. Market Share & Forecast
9.3.5.2.1. By Therapy
9.3.5.2.2. By Animal Type
9.3.5.2.3. By Cancer Type
10. SOUTH AMERICA PET CANCER THERAPEUTICS MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Therapy
10.2.2. By Animal Type
10.2.3. By Cancer Type
10.2.4. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Pet Cancer Therapeutics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Therapy
10.3.1.2.2. By Animal Type
10.3.1.2.3. By Cancer Type
10.3.2. Argentina Pet Cancer Therapeutics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Therapy
10.3.2.2.2. By Animal Type
10.3.2.2.3. By Cancer Type
10.3.3. Colombia Pet Cancer Therapeutics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Therapy
10.3.3.2.2. By Animal Type
10.3.3.2.3. By Cancer Type
11. MIDDLE EAST AND AFRICA PET CANCER THERAPEUTICS MARKET OUTLOOK
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Therapy
11.2.2. By Animal Type
11.2.3. By Cancer Type
11.2.4. By Country
11.3. MEA: Country Analysis
11.3.1. South Africa Pet Cancer Therapeutics Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Therapy
11.3.1.2.2. By Animal Type
11.3.1.2.3. By Cancer Type
11.3.2. Saudi Arabia Pet Cancer Therapeutics Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Therapy
11.3.2.2.2. By Animal Type
11.3.2.2.3. By Cancer Type
11.3.3. UAE Pet Cancer Therapeutics Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Therapy
11.3.3.2.2. By Animal Type
11.3.3.2.3. By Cancer Type
11.3.4. Egypt Pet Cancer Therapeutics Market Outlook
11.3.4.1. Market Size & Forecast
11.3.4.1.1. By Value
11.3.4.2. Market Share & Forecast
11.3.4.2.1. By Therapy
11.3.4.2.2. By Animal Type
11.3.4.2.3. By Cancer Type
11.3.5. Turkey Pet Cancer Therapeutics Market Outlook
11.3.5.1. Market Size & Forecast
11.3.5.1.1. By Value
11.3.5.2. Market Share & Forecast
11.3.5.2.1. By Therapy
11.3.5.2.2. By Animal Type
11.3.5.2.3. By Cancer Type
12. MARKET DYNAMICS
12.1. Drivers
12.2. Challenges
13. MARKET TRENDS & DEVELOPMENTS
14. COMPETITIVE LANDSCAPE
14.1. C.H. Boehringer Sohn Ko. KG
14.2. ELIAS Animal Health, LLC
14.3. Zoetis Inc.
14.4. AB Science S.A.
14.5. Karyopharm Therapeutics, Inc.
14.6. Vivesto AB
14.7. Merial Inc.
14.8. Elanco Animal Health, Inc.
14.9. Dechra Pharmaceuticals PLC (Anivive Lifesciences)
14.10. Torigen Pharmaceuticals Inc.
15. STRATEGIC RECOMMENDATIONS
